AIM ImmunoTech Inc banner
A

AIM ImmunoTech Inc
LSE:0A4Y

Watchlist Manager
AIM ImmunoTech Inc
LSE:0A4Y
Watchlist
Price: 0.72 USD 7.46% Market Closed
Market Cap: $34.5m

Relative Value

0A4Y price has not been updated for more than 9 months. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of 0A4Y.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

0A4Y Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Multiples Across Competitors

0A4Y Competitors Multiples
AIM ImmunoTech Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
AIM ImmunoTech Inc
LSE:0A4Y
3.1m USD 32.6 -0.2 -0.1 -0.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
391.5B USD 6.4 93.5 15.4 21.4
US
Amgen Inc
NASDAQ:AMGN
197.4B USD 5.4 25.6 14.7 14.7
US
Gilead Sciences Inc
NASDAQ:GILD
180.2B USD 6.1 21.2 13.2 16.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.4B USD 9.9 29.9 22.6 23.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80B USD 5.6 17.8 13.2 15.1
AU
CSL Ltd
ASX:CSL
67.7B AUD 3.1 34.4 11.4 14.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
37.7B EUR 10.7 34.5 37.3 38.1
P/S Multiple
Revenue Growth P/S to Growth
US
A
AIM ImmunoTech Inc
LSE:0A4Y
Average P/S: 3 063 005.8
32.6
287%
0.1
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.4
3%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.1
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
10.7
27%
0.4
P/E Multiple
Earnings Growth PEG
US
A
AIM ImmunoTech Inc
LSE:0A4Y
Average P/E: 36.7
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
93.5
97%
1
US
Amgen Inc
NASDAQ:AMGN
25.6
20%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
21.2
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.9
16%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
AU
CSL Ltd
ASX:CSL
34.4
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
34.5
32%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
AIM ImmunoTech Inc
LSE:0A4Y
Average EV/EBITDA: 18.3
Negative Multiple: -0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
12%
1.3
US
Amgen Inc
NASDAQ:AMGN
14.7
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
9%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
18%
0.7
AU
CSL Ltd
ASX:CSL
11.4
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
37.3
50%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
AIM ImmunoTech Inc
LSE:0A4Y
Average EV/EBIT: 20.5
Negative Multiple: -0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.4
24%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.7
3%
4.9
US
Gilead Sciences Inc
NASDAQ:GILD
16.3
13%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
23%
0.7
AU
CSL Ltd
ASX:CSL
14.3
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
38.1
56%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett